In the A549 NSCLC model in vitro, QTPlus‐AM21 significantly induced chemo‐sensitization with erlotinib, a tyrosine kinase inhibitor, by promoting PTEN and inhibiting EGFR expression pharmacologically. This evidence concerns the gene EGFR and non-small cell lung carcinoma.